NON-HODGKIN LYMPHOMA
Clinical trials for NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug injection tested in patients with Tough-to-Treat lymphoma
Disease control TerminatedThis early-stage trial tested a new drug called GEN3017, given as an injection under the skin, for people with advanced Hodgkin and Non-Hodgkin lymphoma that had come back or stopped responding to other treatments. The main goals were to find a safe dose and see how the body hand…
Matched conditions: NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New pill tested as last hope for lymphoma patients
Disease control TerminatedThis early-stage study tested a new oral drug called HMPL-523 in adults with lymphoma that had returned or stopped responding to all approved treatments. The main goals were to find a safe dose and see how the body processes the drug. The study was terminated and involved 69 part…
Matched conditions: NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Experimental Two-Step radiation therapy tested in patients with no other options
Disease control TerminatedThis early-phase study tested a new two-step radioactive treatment for people with advanced non-Hodgkin lymphoma that had returned or stopped responding to standard treatments. The goal was to find safe doses and timing for this experimental therapy, which combines a targeting mo…
Matched conditions: NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Y-mAbs Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Terminated trial tests new combo for tough blood cancers
Disease control TerminatedThis early-phase study aimed to see if combining two targeted drugs, tafasitamab and parsaclisib, was safe and effective for adults whose non-Hodgkin lymphoma or chronic lymphocytic leukemia had returned or stopped responding to prior treatments. The trial enrolled 54 participant…
Matched conditions: NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
CRISPR gene editing used to create 'Ready-Made' cancer therapy
Disease control TerminatedThis study tested a new type of cell therapy called CTX110 for adults with B-cell cancers that have returned or not responded to other treatments. The therapy uses immune cells (T cells) from healthy donors that are modified using CRISPR gene-editing technology to target cancer. …
Matched conditions: NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Early trial halted for new cancer drug targeting multiple advanced cancers
Disease control TerminatedThis early-stage study tested a new drug called PRO1160 in 42 patients with advanced cancers that had spread or returned after previous treatments. The main goals were to find a safe dose and see if the drug could help control kidney cancer, nasopharyngeal cancer, or lymphoma. Th…
Matched conditions: NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC
-
5-Minute breathing device aims to protect cancer Survivors' hearts
Disease control TerminatedThis study tested whether a simple, 5-minute daily breathing exercise using a handheld device could improve heart health and fitness in people who have survived lymphoma. Lymphoma survivors face higher risks of heart problems due to past treatments. The trial was terminated early…
Matched conditions: NON-HODGKIN LYMPHOMA
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Mar 04, 2026 15:30 UTC